Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer

In MONALEESA-2, addition of ribociclib to letrozole resulted in significantly longer progression-free survival (PFS) in postmenopausal women with HR+HER2 − advanced breast cancer (ABC). RIBociclib for the treatment of advanCed breast CAncer (RIBECCA) study investigated ribociclib plus letrozole in a patient population reflecting routine clinical practice.

Source: European Journal of Cancer - December 14, 2023 Category: Cancer & Oncology Authors: Peter A. Fasching, Thomas Decker, Andreas Hartkopf, Arnd Nusch, Bernhard J. Heinrich, Christian Kurbacher, Roswitha Fuchs, Hans Tesch, Petra Krabisch, Jens Huober, Sherko Kuemmel, Sara Brucker, Wolfgang Janni, Andreas Schneeweiss, Martin Schuler, Tanja Fe Tags: Original Research Source Type: research